$LUPIN Receives USFDA Approval for Ranluspec

$LUPIN has secured USFDA approval for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis. The product is the only interchangeable ranibizumab biosimilar approved in the U.S. across both vial and pre-filled syringe formats, covering both approved dosage strengths. The approval strengthens Lupin's biosimilars and specialty portfolio in the high-value ophthalmology segment. With interchangeability status supporting broader market access, the launch could enhance the company's U.S. growth prospects while reinforcing its focus on complex, higher-margin pharmaceutical products.